Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX)
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a passive beneficial ownership of 1.41 million shares, or 5.75%, in Avalo Therapeutics (NASDAQ: AVTX) via a Schedule 13G filing. This disclosure indicates an investment purpose rather than an attempt to control the company. The percentage ownership is calculated based on 24,502,449 shares outstanding as of March 26, 2026, with the reporting persons holding sole voting and dispositive power over these shares.
MAY 13·www.marketscreener.com▲
Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss
Avalo Therapeutics (AVTX) reported a Q1 loss of $0.98 per share, which is better than the FactSet estimate of a $1.03 loss per share. The company is a clinical-stage biotechnology firm focusing on immune dysregulation, with lead asset AVTX-009 for inflammatory diseases.
MAY 13·TradingView→
Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary
Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing increased comprehensive and net losses compared to the previous year. This was attributed to higher spending on advancing clinical and regulatory programs. Financially, the company reported revenue of ($19.7M), net income of ($19.63M), and diluted EPS of ($0.98), alongside positive Phase 2 results for abdakibart and a significant follow-on offering to fund operations for several years.
